Komori
Perseus Proteomics (4882) · FactCited as achieved

U.S. Expanded Phase I Trial and Japan Phase I Trial of PPMX-T002

First written in FY2021. 3 of 8 entries say "Restated". Latest entry: FY2025.

8entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021 – FY2022-Q3SoftenedFY2022AdvancedFY2023Cited as achievedFY2025-H1 – FY20252021: 320212022: 220222023: 120232024: 120242025: 12025
Same theme, other companies
Development of PPMX-T002, a CDH3-targeted radiotherapeutic, in partnership with PPMXA theme 2 companies write about · 0 as a headwind · 3 as a tailwind

0 other companies' latest entry also says "Cited as achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025Cited as achievedAnnual report

    「In a Phase I trial conducted in the US by Fujifilm Corporation in patients with advanced solid tumors, accumulation of the PPMX-T002 antibody in the tumor tissue of treated patients and safety were confirmed at the administered dose, and tumor shrinkage was observed in some cases. In a clinical trial involving Stage IV patients, favorable results were obtained, with SD (stable disease) or CR (complete remission) achieved in 11 of 15 cases.」

    Discloses that SD or CR was achieved in 11 of 15 cases in Fujifilm Corporation's Phase I trial in the US.
  2. FY2025-H1Cited as achievedAnnual report

    「In the expanded Phase I trial conducted in the United States by a subsidiary of FUJIFILM, the antibody was confirmed to accumulate in the targeted cancer cells.」

    Cites the record of target-antibody accumulation in cancer cells in an expanded Phase I trial conducted in the US by a subsidiary of Fujifilm Corporation for PPMX-T002.
  3. FY2023AdvancedAnnual report

    「FUJIFILM Toyama Chemical Co., Ltd.'s domestic Phase I trial of PPMX-T002 was discontinued in connection with the transfer of its radiopharmaceutical business.」

    In addition to the policy of discontinuing development after completion of the U.S. trial, the company disclosed that the domestic Phase I trial was discontinued in connection with the transfer of the radiopharmaceutical business.
  4. FY2022SoftenedAnnual report

    「The expanded Phase I trial in the United States has been ongoing since 2019, and the domestic Phase I trial has been ongoing since April 2020. However, following completion of both trials, FUJIFILM Corporation will discontinue development of PPMX-T002.」

    Although the U.S. and domestic trials are continuing, the company has stated that FUJIFILM plans to discontinue development of PPMX-T002 after the ongoing trials are completed.
  5. FY2022-Q3RestatedAnnual report

    「The Phase I trial was expanded in 2019, with the number of cases increased at the maximum tolerated dose, and a trial equivalent to a Phase II trial under the standards of Japan's Ministry of Health, Labour and Welfare is being conducted. In addition, FUJIFILM Toyama Chemical Co., Ltd. has been conducting a domestic Phase I trial since April 2020.」

    The company reconfirmed that the FUJIFILM Group continues to conduct the expanded Phase I trial in the United States and the domestic Phase I trial.
  6. FY2022-Q2RestatedAnnual report

    「The Phase I trial was expanded in 2019, with the number of cases increased at the maximum tolerated dose, and a trial equivalent to a Phase II trial under the standards of Japan's Ministry of Health, Labour and Welfare is being conducted. In addition, FUJIFILM Toyama Chemical Co., Ltd. has been conducting a domestic Phase I trial since April 2020.」

    The company reconfirmed that the FUJIFILM Group continues to conduct the expanded Phase I trial in the United States and the domestic Phase I trial.
  7. FY2022-Q1RestatedAnnual report

    「The Phase I trial was expanded in 2019, with the number of cases increased at the maximum tolerated dose, and a trial equivalent to a Phase II trial under the standards of Japan's Ministry of Health, Labour and Welfare is being conducted. In addition, FUJIFILM Toyama Chemical Co., Ltd. has been conducting a domestic Phase I trial since April 2020.」

    The company reconfirmed that the FUJIFILM Group continues to conduct the expanded Phase I trial in the United States and the domestic Phase I trial.
  8. FY2021First statedAnnual report

    「In the United States, the company has been conducting an expanded Phase I trial since 2019, increasing the number of cases at the maximum tolerated dose. This expanded Phase I trial is equivalent to a Phase II trial under the standards of Japan's Ministry of Health, Labour and Welfare. A domestic Phase I trial also began in April 2020.」

    The company stated that the U.S. expanded Phase I trial and domestic Phase I trial were being conducted by its licensee, FUJIFILM.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Perseus Proteomics yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
U.S. Expanded Phase I Trial and Japan Phase I Trial of PPMX-T002 | Perseus Proteomics Inc. (4882) | Komori